We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genes Required for Cancer Cell Transformation Found

By Biotechdaily staff writers
Posted on 22 Jun 2004
Researchers studying the molecular biologic mechanisms responsible for the transformation of normal cells into cancer cells have identified a core group of 67 genes whose activity is required for transformation to occur.

Investigators at the University of Michigan (Ann Arbor, USA; www.umich.edu) collected and analyzed 40 published cancer microarray data sets, comprising 38 million gene expression measurements from more than 3,700 cancer samples. More...
To cope with this massive amount of data they developed a statistical method, comparative meta-profiling, to identify and assess the intersection of multiple gene expression signatures from the diverse collection of microarray data sets.

They characterized a common transcriptional profile comprising 67 genes that is universally activated in most cancer types relative to the normal tissues from which they arose, likely reflecting essential transcriptional features of neoplastic transformation. In addition, they characterized a transcriptional profile of 69 other genes that is commonly activated in various types of undifferentiated cancer, suggesting common molecular mechanisms by which cancer cells progress and avoid differentiation. These findings were published in the June 7, 2004, online edition of the Proceedings of the [U.S.] National Academy of Sciences.

"This paper is the first to report common patterns of genetic activity across multiple cancer microarray datasets from different investigators,” said senior author Dr. Arul M. Chinnaiyan, associate professor of pathology and urology at the University of Michigan. "These genes and their associated proteins are the molecular components that make different types of cancer more similar to each other than to normal tissue. Since these genes appear to be involved in so many types of cancer, they are prime targets for new cancer-fighting drugs.”




Related Links:
University of Michigan

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.